• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An extended release preparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non ionic solubilizer and whereby the amount by weight of the solubilizer is at least equal to the amount by weight of the active compound as well as a process for the preparation thereof.
    公开号:SU1743332A3
    申请号:SU874202349
    申请日:1987-04-10
    公开日:1992-06-23
    发明作者:Фалк Леннарт Карл-Эрик；Морган Хугоссон Свен；Росински Адам；Альберт Сьерген Джон
    申请人:Актиеболагет Хассле (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to the chemical and pharmaceutical industry and concerns the preparation of tablets.
    The aim of the invention is to increase the bioavailability of the active substance.
    PRI me R 1. The composition contains: Felodipin10
    Fatty acid ester of hydrogenated castor oil with oxyethylated glycerol (Cremophor RH-40) 90
    Calcium Phosphate 250
    Hydroxypropylmethyl cellulose 250 Xanthan gum25
    Guarova resin25
    Sodium fumarate 13
    The composition is molded into tablets with a hydrophilic matrix containing 10 mg felodipine per tablet.
    Tablets prepared as follows.
    Felodipine is dissolved in Cremophor RH-40 and the resulting solution is thoroughly mixed with carrier, hydroxypropylmethylcellulose, xanthan gum, guar gum and calcium phosphate. The mixture is granulated with ethanol and dried. Sodium fumarate is added as a lubricant to obtain tablets by compression in a tablet machine.
    PRI mme R 2. The composition contains: Felodipin10
    Cremophor RH-6090
    Aluminum silicate 100
    vj
    N
    CJ
    so co

    with
    Paraffin80
    Hydroxypropylcellulose7,4
    Sodium fumarate 5.0
    The composition according to example 2 is formed into tablets with a controlled yield of the inert porous matrix type, containing 10 mg felodipine per tablet.
    Tablets prepared as follows.
    Felodipine is dissolved in Cremophor RH60 and the resulting solution is thoroughly mixed with carriers, aluminum silicate and paraffin. The mixture is granulated with a solution of hydroxypropylcellulose in ethanol and dried. Sodium fumarate was added as a lubricant and the tablets were prepared by pressing into a tableting machine. According to in vitro tests, controlled release of felodipine is achieved, namely, 50% is excreted in 2 hours and 100% in 6 hours.
    PRI me R 3. The composition contains: Felodipin 20
    Cremophor RH 40100
    Polyvinylpyrrolidone66,5
    Microcrystalline Cellulose62
    Maize starch29,5
    Lactose157
    Ethyl cellulose36
    Hydroxypropylcellulose12
    Gelatin capsules The composition according to example 3 is formed into capsules with controlled release, containing 20 mg felodipine per 1 capsule.
    Capsules are prepared as follows. Felodipine is dissolved in Cremophor and the resulting solution is thoroughly mixed with a carrier, polyvinylpyrrolidone, cellulose, maize starch and lactose. The mixture is moistened with water and spheronized. The resulting granules are dried and sieved using fractions of 0.71-1.12 mm. The granules are coated with ethyl cellulose dissolved in a mixture of methylene chloride and ethanol. The coated granules are introduced into hard gelatin capsules.
    PRI me R 4. The composition contains: Felodipin 20
    Mjrj51120
    Hydroxy polypropyl methyl methyl cellulose200
    Microcrystalline cellulose 20
    Lactose167
    Sodium fumarate 10.5
    The composition of Example 4 is formed into controlled release tablets containing 20 mg of felodipine per tablet. Tablets prepared analogously to example 1.
    PRI me R 5. The composition contains: Nifedipin 20
    Cremophor RH 4050
    Hydroxypropylmethylcellulose 70 Hydroxypropylmethylcellulose 2910.6 Sp160
    Microcrystalline cellulose 6 Lactose56
    Aluminum silicate 94
    0 sodium fumarate 10
    The composition according to example 5 is molded into tablets with a hydrophilic matrix containing 20 mg of nifedipine per tablet. Tablets are prepared as in Example 1. 5 Example (comparative). The following example illustrates the comparative tablets used in in vitro tests.
    The composition contains:
    0Felodipin25
    Lactose 250
    Methyl cellulose 0.5
    Polyvinylpyrrolidone1,5
    Magnesium stearate 3
    5 The composition according to Example 6 is formed into instant conventional tablets containing 25 mg of felodipine per tablet.
    Tablets prepared as follows.
    0 Felodipine is ground to micron-sized particles and mixed with lactose and methylcellulose. The mixture is granulated with water and dried. Polyvinylpyrrolidone and magnesium stearate are added and the mass is compressed into 5 tablets.
    Example. The composition contains: ethyl cellulose number 1034
    Polyethylene glycol 600041,8
    The composition according to example 7 is formed into capsules 0 of a controlled release, containing 10 mg of felodipine per capsule.
    Capsules are prepared as follows. Felodipine is ground to micron-sized particles and thoroughly mixed with 5 carrier, mannitol, methylcellulose, polyvinylpyrrolidone and cellulose. The mixture is moistened with water and spheronized. The obtained granules are dried and sieved, selecting a fraction of 0.71-1.12 mm. The granules are coated with ethyl cellulose and polyethylene glycol dissolved in a mixture of methylene chloride and isopropyl alcohol. The coated granules are introduced into hard gelatin capsules. 5 Biopharmaceutical testing.
    A single dose of 20 mg of felodipine was administered to six healthy men in the form of a sustained release formulation according to the invention. The concentration of felodipine in plasma is compared with
    plasma concentrations after a single dose as an instant tablet containing 25 mg felodipine. The formulations of the invention give a lower peak plasma concentration than a quick-dissolving tablet, giving an undesirable high peak.
    The values of the area under the curve of plasma concentration versus time (AIS) for time from 0 to infinity are given in the table.
    As can be seen from the table, felodipine bioassimilability is not reduced when using compositions with controlled release.
    The described examples illustrate the advantages of the proposed formulations in comparison with the known, where all the formulations contain the same active agent. With the active compound having a very low solubility, it is possible to obtain tablets having a more constant plasma concentration profile without undesired high peaks. In addition, the effect is observed for a longer time. With the introduction of the compositions of drugs with very low solubility
    a decrease in bioavailability is often observed. The invention provides a method for producing controlled drug release formulations of very low solubility, having the above advantages without any significant reduction in bioavailability.
    权利要求:
    Claims (1)
    [1]
    Claim preparation method by mixing the substituted dihydropyridine with excipients and tabletting, characterized in that, in order to improve the bioavailability of the active substance, the substituted dihydropyridine, nifedipine or felodipine is dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer. esters of complex acids, hydrogenated castor oil with oxyethylated glycerol complex esters of polyethoxylated fatty acids in the amount of 1: 2.5 d about 1: 9 with respect to the active substance and the mixture is granulated with hydrophilic gel - hydroxypropylmethyl cellulose.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1743332A3|1992-06-23|Process for producing tablets
    FI92903B|1994-10-14|Method of preparation of a long-acting pharmaceutical preparation
    EP0142561B1|1989-06-14|Long-acting nifedipine preparation
    US4454108A|1984-06-12|Prolonged-action multiple-layer tablets
    US4404183A|1983-09-13|Sustained release pharmaceutical composition of solid medical material
    US6348490B1|2002-02-19|Dosage forms containing thioctic acid or solid salts of thioctic acid with improved release and bioavailability
    WO2009034541A9|2009-12-30|Controlled release pharmaceutical dosage forms of trimetazidine
    US5268182A|1993-12-07|Sustained-release drug dosage units of terazosin
    GB2196851A|1988-05-11|Sustained release composition
    JPH11512115A|1999-10-19|Pharmaceutical composition for oral administration
    JPH0640928A|1994-02-15|Percutaneous medicine composition containing anthocyanoxides
    US6451343B1|2002-09-17|Composition for treating dementia and Alzheimer's disease
    US6383517B1|2002-05-07|Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
    EA008171B1|2007-04-27|Pharmaceutical formulation comprising fosinopril
    SK284584B6|2005-07-01|Controlled-release tablet
    IE59293B1|1994-02-09|Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions
    JPH1192369A|1999-04-06|Pharmaceutical preparation, its production and use of acidic additive for stabilization of cilansetron
    US5069911A|1991-12-03|Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
    KR20010078703A|2001-08-21|New Pharmaceutical Formulation
    US7014864B1|2006-03-21|Formulations comprising lipid-regulating agents
    IE59589B1|1994-03-09|Pharmaceutical formulations with controlled release of the active substance
    CA2531097C|2012-10-09|Process for preparing formulations of lipid-regulating drugs
    WO1999007370A1|1999-02-18|Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation
    SI8710407A|1996-08-31|Process for obtaining solid pharmaceutical preparation with extended release of active compound
    同族专利:
    公开号 | 公开日
    YU47258B|1995-01-31|
    SE8601624D0|1986-04-11|
    FI91826B|1994-05-13|
    UA12336A|1996-12-25|
    IS1553B|1994-08-10|
    JPH0778016B2|1995-08-23|
    EG18265A|1992-12-30|
    PH22494A|1988-09-12|
    PT84663B|1989-11-30|
    KR950002147B1|1995-03-14|
    CS258787A2|1989-11-14|
    DZ1067A1|2004-09-13|
    NO871199L|1987-10-12|
    MY101553A|1991-12-17|
    AT76288T|1992-06-15|
    EP0249587A1|1987-12-16|
    CY1826A|1995-12-01|
    CA1304294C|1992-06-30|
    FI871585A|1987-10-12|
    NO174795C|1994-07-13|
    DK154987A|1987-10-12|
    ES2031929T3|1993-01-01|
    DE3779183D1|1992-06-25|
    AU602677B2|1990-10-25|
    SG4295G|1995-06-16|
    NO174795B|1994-04-05|
    PT84663A|1987-05-01|
    PL265078A1|1988-07-21|
    IE59419B1|1994-02-23|
    ZA871911B|1987-12-30|
    US4803081A|1989-02-07|
    DD263231A5|1988-12-28|
    NO871199D0|1987-03-23|
    NZ219633A|1989-11-28|
    YU40787A|1992-09-07|
    HU204699B|1992-02-28|
    EP0249587B1|1992-05-20|
    IE870925L|1987-10-11|
    CN1025150C|1994-06-29|
    FI91826C|1994-08-25|
    CN87102758A|1987-10-21|
    KR870009720A|1987-11-30|
    KR890001521A|1989-03-27|
    AU7004387A|1987-10-15|
    HK26795A|1995-03-10|
    JPS62242613A|1987-10-23|
    IS3214A7|1987-10-12|
    DK173033B1|1999-11-29|
    DK154987D0|1987-03-26|
    FI871585A0|1987-04-10|
    GR3005286T3|1993-05-24|
    HUT43786A|1987-12-28|
    CS270560B2|1990-07-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US8518421B2|2000-04-12|2013-08-27|Bristol-Myers Squibb Company|Flashmelt oral dosage formulation|DE2714065A1|1977-03-30|1978-10-12|Boehringer Mannheim Gmbh|INSTILLATION PREPARATION|
    JPS612046B2|1978-01-11|1986-01-22|Nippon Kayaku Kk|
    CA1146866A|1979-07-05|1983-05-24|Yamanouchi Pharmaceutical Co. Ltd.|Process for the production of sustained releasepharmaceutical composition of solid medicalmaterial|
    JPS58109412A|1981-12-23|1983-06-29|Toa Eiyou Kagaku Kogyo Kk|Nifedipine solid preparation|
    DE3318649A1|1983-05-21|1984-11-22|Bayer Ag, 5090 Leverkusen|TWO-PHASE FORMULATION|
    DE3400106A1|1984-01-04|1985-07-11|Klaus-Dieter Dr. 3550 Marburg Bremecker|Pharmaceutical compositions with controlled release of medicinal substance|
    KR850700212A|1984-03-21|1985-12-26|죠지 드모트|Sustained Release Pharmaceutical Wexel|
    JPS618A|1984-06-09|1986-01-06|Sawai Seiyaku Kk|Nifedipin-containing drug preparation|
    IT1178511B|1984-09-14|1987-09-09|Pharmatec Spa|PROCEDURE FOR THE PREPARATION OF A SOLID FORM FOR ORAL USE BASED ON NIFEDIPINE WITH RELEASE|
    IT1187751B|1985-10-15|1987-12-23|Eurand Spa|PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED|DE3720757A1|1987-06-24|1989-01-05|Bayer Ag|DHP COAT TABLET|
    NO883326L|1987-08-11|1989-02-13|Bayer Ag|DHP-retard-COOK.|
    DE3738236A1|1987-11-11|1989-05-24|Euro Celtique Sa|BIT CAPSULE|
    US6007840A|1988-09-16|1999-12-28|Novartis Ag|Pharmaceutical compositions comprising cyclosporins|
    KR0148748B1|1988-09-16|1998-08-17|장 크라메르, 한스 루돌프 하우스|A multiphase cyclosporin composition|
    US4946684A|1989-06-20|1990-08-07|American Home Products Corporation|Fast dissolving dosage forms|
    US5006344A|1989-07-10|1991-04-09|E. R. Squibb & Sons, Inc.|Fosinopril tablet formulations|
    HU208491B|1990-11-27|1993-11-29|Gyogyszerkutato Intezet|Process for producing oral pharmaceutical composition containing cyclosporin|
    US5834496A|1991-12-02|1998-11-10|Sepracor, Inc.|Methods for treating hypertension using optically pure S felodipine|
    US5681812A|1991-12-10|1997-10-28|Rush Presbyterian-St. Luke's Medical Center|Methods and compositions for reducing multidrug resistance|
    AU3243393A|1991-12-10|1993-07-19|Rush - Presbyterian - St. Luke's Medical Center|Methods and compositions for reducing multi-drug resistance|
    GB9200607D0|1992-01-13|1992-03-11|Ethical Pharma Ltd|Pharmaceutical compositions containing nifedipine and process for the preparation thereof|
    SG45449A1|1992-05-13|1998-01-16|Sandoz Ltd|Ophthalmic compositions|
    US6262022B1|1992-06-25|2001-07-17|Novartis Ag|Pharmaceutical compositions containing cyclosporin as the active agent|
    US5472711A|1992-07-30|1995-12-05|Edward Mendell Co., Inc.|Agglomerated hydrophilic complexes with multi-phasic release characteristics|
    JP3598049B2|1992-09-18|2004-12-08|山之内製薬株式会社|Hydrogel sustained release formulation|
    RO112991B1|1992-09-18|1998-03-30|Yamanouchi Pharma Co Ltd|Sustained release hydrogel-type preparation|
    DK0589843T3|1992-09-25|2002-04-02|Novartis Ag|Cyclosporin-containing pharmaceutical preparations|
    BE1006990A5|1993-04-22|1995-02-07|Univ Gent|METHOD AND COMPOSITION TO MAKE AN ACTIVE INGREDIENT IN A solid dosage form.|
    US6726930B1|1993-09-09|2004-04-27|Penwest Pharmaceuticals Co.|Sustained release heterodisperse hydrogel systems for insoluble drugs|
    US5773025A|1993-09-09|1998-06-30|Edward Mendell Co., Inc.|Sustained release heterodisperse hydrogel systems--amorphous drugs|
    US5455046A|1993-09-09|1995-10-03|Edward Mendell Co., Inc.|Sustained release heterodisperse hydrogel systems for insoluble drugs|
    US20060263428A1|1993-09-20|2006-11-23|Eugenio Cefali|Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics|
    US6080428A|1993-09-20|2000-06-27|Bova; David J.|Nicotinic acid compositions for treating hyperlipidemia and related methods therefor|
    US6746691B2|1993-09-20|2004-06-08|Kos Pharmaceuticals, Inc.|Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics|
    US6818229B1|1993-09-20|2004-11-16|Kos Pharmaceuticals, Inc.|Intermediate release nicotinic acid compositions for treating hyperlipidemia|
    US6676967B1|1993-09-20|2004-01-13|Kos Pharmaceuticals, Inc.|Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia|
    US6129930A|1993-09-20|2000-10-10|Bova; David J.|Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night|
    DE4340781C3|1993-11-30|2000-01-27|Novartis Ag|Liquid preparations containing cyclosporin and process for their preparation|
    US5945125A|1995-02-28|1999-08-31|Temple University|Controlled release tablet|
    US5783212A|1996-02-02|1998-07-21|Temple University--of the Commonwealth System of Higher Education|Controlled release drug delivery system|
    MX9801835A|1996-07-08|1998-08-30|Mendell Co Inc Edward|Sustained release matrix for high-dose insoluble drugs.|
    KR20050084502A|1997-01-30|2005-08-26|노파르티스 아게|Oil-free pharmaceutical compositions containing cyclosporin a|
    US5895663A|1997-07-31|1999-04-20|L. Perrigo Company|Pseudoephedrine hydrochloride extended-release tablets|
    AR016827A1|1997-08-22|2001-08-01|Smithkline Beecham Corp|PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET|
    AR017512A1|1997-08-22|2001-09-12|Smithkline Beecham Corp|TABLETS OF QUICKLY DISPOSABLE METILCELLULOSE FOR ORAL ROUTE ADMINISTRATION AND PROCEDURE TO PREPARE THEM|
    US6056977A|1997-10-15|2000-05-02|Edward Mendell Co., Inc.|Once-a-day controlled release sulfonylurea formulation|
    JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|
    US6555139B2|1999-06-28|2003-04-29|Wockhardt Europe Limited|Preparation of micron-size pharmaceutical particles by microfluidization|
    SE9902742D0|1999-07-20|1999-07-20|Astra Ab|New pharmaceutical formultion|
    ES2304980T3|1999-09-30|2008-11-01|Penwest Pharmaceuticals Co.|SUSTAINED LIBERATION MATRIX SYSTEMS FOR HIGHLY SOLUBLE PHARMACOS.|
    FR2802424B1|1999-12-17|2002-02-15|Adir|MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION|
    GB0001449D0|2000-01-21|2000-03-08|Cortendo Ab|Compositions|
    PL201513B1|2000-04-11|2009-04-30|Sankyo Co|Stabilized pharmaceutical compositions containing calcium channel blockers|
    TWI324074B|2001-10-09|2010-05-01|Squibb Bristol Myers Co|Flashmelt oral dosage formulation|
    SE0004671D0|2000-12-15|2000-12-15|Amarin Dev Ab|Pharmaceutical formulation|
    WO2002056883A1|2001-01-18|2002-07-25|Wockhardt Limited|Preparation of micron-size felodipine particles by microfluidization|
    US20040214849A1|2001-07-06|2004-10-28|Huai-Hung Kao|Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic|
    JP2005508330A|2001-09-28|2005-03-31|マクニール−ピーピーシー・インコーポレイテッド|Composite dosage form with filled part|
    US8101209B2|2001-10-09|2012-01-24|Flamel Technologies|Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles|
    US6726931B2|2002-04-08|2004-04-27|Standard Chem. & Pharm. Co., Ltd.|Process for preparing oral sustained-release formulation of felodipine|
    IL164221D0|2002-04-09|2005-12-18|Flamel Tech Sa|Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim|
    DE60325709D1|2002-04-09|2009-02-26|Flamel Tech Sa|ORAL AQUEOUS SUSPENSION CONTAINING MICRO CAPSULES FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES|
    US20030211149A1|2002-05-07|2003-11-13|Sherman Bernard Charles|Extended release tablets comprising felodipine|
    JP4563642B2|2002-05-31|2010-10-13|ワトソンラボラトリーズ、インコーポレイテッド|Pharmaceutical formulation|
    FR2842736B1|2002-07-26|2005-07-22|Flamel Tech Sa|ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A PLURALITY OF MICROCAPSULES FOR PROLONGED RELEASE OF LOW SOLUBLE ACTIVEPRINCIPLE |
    FR2842735B1|2002-07-26|2006-01-06|Flamel Tech Sa|MODIFIED RELEASE MICROCAPSULES OF LOW SOLUBLE ACTIVE PRINCIPLES FOR PER OS ADMINISTRATION|
    CN100473378C|2002-12-17|2009-04-01|阿伯特有限及两合公司|Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof|
    US20080051411A1|2002-12-17|2008-02-28|Cink Russell D|Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof|
    US7259186B2|2002-12-17|2007-08-21|Abbott Laboratories|Salts of fenofibric acid and pharmaceutical formulations thereof|
    US20050032879A1|2003-08-07|2005-02-10|Temple Okarter|Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases|
    TWI372066B|2003-10-01|2012-09-11|Wyeth Corp|Pantoprazole multiparticulate formulations|
    US8987322B2|2003-11-04|2015-03-24|Circ Pharma Research And Development Limited|Pharmaceutical formulations for carrier-mediated transport statins and uses thereof|
    US20070196396A1|2004-02-11|2007-08-23|Rubicon Research Private Limited|Controlled release pharmaceutical compositions with improved bioavailability|
    KR100598326B1|2004-04-10|2006-07-10|한미약품 주식회사|EXTENDED RELEASE ORAL FORMULATION OF HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF|
    US20080152714A1|2005-04-08|2008-06-26|Yi Gao|Pharmaceutical Formulations|
    TW200806648A|2005-11-29|2008-02-01|Sankyo Co|Acid addition salts of dihydropyridine derivatives|
    TW200736245A|2005-11-29|2007-10-01|Sankyo Co|Acid addition salts of optically active dihydropyridine derivatives|
    CN101103964B|2006-07-14|2010-09-29|海南盛科生命科学研究院|Sustained-release preparation containing felodipine and preparation method thereof|
    US20080081067A1|2006-10-03|2008-04-03|Gupta Manishkumar|Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof|
    JP6025820B2|2011-04-20|2016-11-16|フリースケール セミコンダクター インコーポレイテッド|Amplifier and associated integrated circuit|
    CN104997750B|2015-07-30|2018-03-20|杭州康恩贝制药有限公司|A kind of felodipine sustained-release tablets and preparation method thereof|
    US9675585B1|2016-03-24|2017-06-13|Ezra Pharma|Extended release pharmaceutical formulations|
    US9687475B1|2016-03-24|2017-06-27|Ezra Pharma Llc|Extended release pharmaceutical formulations with controlled impurity levels|
    CN109200026B|2017-07-03|2021-01-05|北京四环科宝制药有限公司|Felodipine sustained-release tablet and preparation method thereof|
    JP2021527269A|2018-06-14|2021-10-11|アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ|Dihydropyridine Calcium Channel Blocker Methods for Lowering Blood Pressure Using Pharmaceutical Compositions|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE8601624A|SE8601624D0|1986-04-11|1986-04-11|NEW PHARMACEUTICAL PREPARATIONS|LTRP950A| LT2256B|1986-04-11|1993-09-06|THE TALK OF THE TABLET|
    [返回顶部]